Verastem reported $22.3M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.84B 205M Sep/2026
Alaunos Therapeutics USD 424K 23K Jun/2026
AstraZeneca USD 4.07B 1.73B Sep/2026
Curis USD 2.96M 1.62M Mar/2026
Cytokinetics USD 113.14M 8.75M Sep/2026
Gilead Sciences USD 1.52B 70M Jun/2026
Incyte USD 364.27M 12.54M Sep/2026
Laboratory Of America USD 611.4M 34.2M Sep/2026
Novartis USD 3.08B 163M Sep/2026
Pfizer USD 3.28B 132M Sep/2026
Roche Holding CHF 6.37B 908M Jun/2026
TG Therapeutics USD 62.32M 10.82M Jun/2026
Verastem USD 22.3M 2.14M Mar/2026